BioSante Expects Estradiol, Testosterone Gel Filings In 2004; Marketing Will Ride Solvay Coattails
This article was originally published in The Pink Sheet Daily
Executive Summary
Company aims to capture 10%-20% of the testosterone gel market with Bio-T-Gel. Female sexual dysfunction will be next frontier for BioSante gels, with Procter & Gamble as trailblazer in FSD market, BioSante CEO says.